Seminars in Nuclear Medicine
- Print ISSN
- Electronic ISSN
- Impact factor
- Usage rank
- Article count
- Free count
- Free percentage
- PDFs via platforms
- Gale, Sciencedirect from 1971, Proquest, and CSA
Current and future trends in the anatomical and functional imaging of head and neck paragangliomas.
Head and neck paragangliomas (HNPGLs) account for approximately 3% of all paragangliomas (PGLs). Most often, HNPGLs are benign, nonsecreting, and slowly progressing. The initial physical examination and biochemical diagnosis usually adds very little to the proper diagnosis of these tumors, and, ther...
Letter from the editors.
Positron emission tomography in renal cell carcinoma: an imaging biomarker in development.
We will start with a brief overview of the demographics, molecular pathogenesis, and evolving treatment strategies in RCC because this information is essential for better understanding of uptake of various PET radiotracers in this cancer and their indications. This will be followed by discussing the...
Decreased sensitivity of (18)F-fluorodeoxyglucose imaging in infection and inflammation.
Nuclear medicine plays an important role in the evaluation of inflammation and infection. Although (99m)Tc-methylene diphosphonate, (67)Ga-citrate, and in vitro labeled autologous leukocyte imaging are useful procedures, there are limitations to each of them. (18)F-fluorodeoxyglucose-positron-emissi...
Concepts, consequences, and implications of theranosis.
Although the term has been coined recently, the concepts underlying theranosis have been applied in patient care for more than one-half century. However, advanced technologies are used now. Theranosis describes processes used to tailor therapy for a patient. It is the use of diagnostic tests to iden...
In Memoriam: Alexander Gottschalk, MD (1932-2010)
Design of Clinical Trials
Clinical trial design for nuclear medicine diagnostic imaging radiopharmaceuticals must include a design for preclinical safety studies. These studies should establish that the investigational product (IP) does not have a toxic effect. As a further requirement, radiopharmaceutical cl...
Seminars in Nuclear Medicine. Selected pharmacologic interventions and monitoring. Letter from the editors.
Risks to normal tissues from radionuclide therapy.
The development of radionuclide therapies during the past few decades provides a growing body of data on radiobiologic effects, including normal tissue toxicities and antitumor efficacy. Information on normal tissue toxicity from radionuclides is more limited than that from external beam radiation a...
Developments in instrumentation. Letter from the editors.